FDA approves Eli Lilly diabetes drug

Tirzepatide, a treatment for type 2 diabetes developed by Eli Lilly, has been approved by the FDA, setting the stage for a direct competition with Novo Nordisk’s Ozempic.
Photo: MIKE SEGAR/REUTERS / X90033
Photo: MIKE SEGAR/REUTERS / X90033
by marketwire, translated by daniel pedersen

On Friday, US-based pharmaceutical firm Eli Lilly could announce that the US Food and Drug Administration (FDA) has approved tirzepatide for patients with type 2 diabetes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading